These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 38097870)
1. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Liu Y; Cao Y; Liu P; Zhai S; Liu Y; Tang X; Lin J; Shi M; Qi D; Deng X; Zhu Y; Wang W; Shen B Cell Oncol (Dordr); 2024 Jun; 47(3):939-950. PubMed ID: 38097870 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions. Kwon M; Jang H; Kim EH; Roh JL Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
4. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression. Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461 [TBL] [Abstract][Full Text] [Related]
6. Poly-(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-κB in THP-1 monocytes. Mustafa K; Han Y; He D; Wang Y; Niu N; Jose PA; Jiang Y; Kopp JB; Lee H; Qu P PLoS One; 2024; 19(2):e0295837. PubMed ID: 38335214 [TBL] [Abstract][Full Text] [Related]
7. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029 [TBL] [Abstract][Full Text] [Related]
8. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889 [TBL] [Abstract][Full Text] [Related]
9. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440 [TBL] [Abstract][Full Text] [Related]
10. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT Cells; 2020 Apr; 9(4):. PubMed ID: 32276472 [TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]